Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells
- PMID: 9719462
- DOI: 10.1016/s0304-3835(98)00104-9
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells
Abstract
Ribonucleotide reductase, a key enzyme in deoxyribonucleotide synthesis, is an important target for cancer chemotherapy. Drugs that inhibit its individual components may act synergistically to block DNA synthesis. Prior work has established that gallium inhibits the R2 subunit of ribonucleotide reductase. We show that gallium acts synergistically with the ribonucleotide reductase inhibitors gemcitabine and hydroxyurea to inhibit the proliferation of CCRF-CEM cells. In contrast, combinations of gallium with the ribonucleotide reductase inhibitors amidox, didox, or trimidox produced antagonistic effects on cell growth. Spectroscopy analysis revealed that as a result of their metal-binding properties, amidox, didox and trimidox formed complexes with gallium, thus negating potential synergistic actions. Our results have important implications in the design of clinical trials using these ribonucleotide reductase inhibitors in combination.
Similar articles
-
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.Adv Enzyme Regul. 1991;31:71-83. doi: 10.1016/0065-2571(91)90009-b. Adv Enzyme Regul. 1991. PMID: 1877400
-
Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.Am J Hematol. 2000 Apr;63(4):176-83. doi: 10.1002/(sici)1096-8652(200004)63:4<176::aid-ajh3>3.0.co;2-g. Am J Hematol. 2000. PMID: 10706760
-
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.Life Sci. 1997;61(22):2231-7. doi: 10.1016/s0024-3205(97)00925-9. Life Sci. 1997. PMID: 9393942
-
[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases].Wien Klin Wochenschr. 1995;107(22):694-7. Wien Klin Wochenschr. 1995. PMID: 8533431 Review. German.
-
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.Expert Rev Anticancer Ther. 2002 Aug;2(4):437-48. doi: 10.1586/14737140.2.4.437. Expert Rev Anticancer Ther. 2002. PMID: 12647987 Review.
Cited by
-
Quantitative proteomic reveals gallium maltolate induces an iron-limited stress response and reduced quorum-sensing in Pseudomonas aeruginosa.J Biol Inorg Chem. 2020 Dec;25(8):1153-1165. doi: 10.1007/s00775-020-01831-x. Epub 2020 Oct 30. J Biol Inorg Chem. 2020. PMID: 33125529
-
The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1.Oncotarget. 2020 Apr 28;11(17):1531-1544. doi: 10.18632/oncotarget.27567. eCollection 2020 Apr 28. Oncotarget. 2020. PMID: 32391122 Free PMC article.
-
Gallium-containing anticancer compounds.Future Med Chem. 2012 Jun;4(10):1257-72. doi: 10.4155/fmc.12.69. Future Med Chem. 2012. PMID: 22800370 Free PMC article. Review.
-
Medical applications and toxicities of gallium compounds.Int J Environ Res Public Health. 2010 May;7(5):2337-61. doi: 10.3390/ijerph7052337. Epub 2010 May 10. Int J Environ Res Public Health. 2010. PMID: 20623028 Free PMC article. Review.
-
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).Curr Cancer Drug Targets. 2009 Aug;9(5):595-607. doi: 10.2174/156800909789056962. Epub 2009 Aug 1. Curr Cancer Drug Targets. 2009. PMID: 19508176 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources